These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19275632)

  • 61. Alzheimer's amyloid immunotherapy: quo vadis?
    Gandy S; Heppner FL
    Lancet Neurol; 2005 Aug; 4(8):452-3. PubMed ID: 16033686
    [No Abstract]   [Full Text] [Related]  

  • 62. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
    Bacskai BJ; Kajdasz ST; McLellan ME; Games D; Seubert P; Schenk D; Hyman BT
    J Neurosci; 2002 Sep; 22(18):7873-8. PubMed ID: 12223540
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
    Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML
    Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Amyloid immunotherapy-engendered CNS inflammation.
    Bowers WJ; Federoff HJ
    Neurobiol Aging; 2002; 23(5):675-6; discussion 683-4. PubMed ID: 12392770
    [No Abstract]   [Full Text] [Related]  

  • 66. [Aβ42 gene vaccine for prevention and treatment of Alzheimer's disease].
    Rosenberg RN
    Rinsho Shinkeigaku; 2010 Nov; 50(11):838. PubMed ID: 21921464
    [No Abstract]   [Full Text] [Related]  

  • 67. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
    van Dyck CH
    Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.
    Liu S; Shi D; Wang HC; Yu YZ; Xu Q; Sun ZW
    Sci Rep; 2015 Jan; 5():7771. PubMed ID: 25586780
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Development of therapies of Alzheimer's disease].
    Shoji M
    Nihon Ronen Igakkai Zasshi; 2003 Sep; 40(5):473-5. PubMed ID: 14579716
    [No Abstract]   [Full Text] [Related]  

  • 70. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.
    Lambert MP; Velasco PT; Viola KL; Klein WL
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):65-81. PubMed ID: 19275637
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.
    Wang YJ
    Nat Rev Neurol; 2014 Apr; 10(4):188-9. PubMed ID: 24638135
    [No Abstract]   [Full Text] [Related]  

  • 73. Follow-up of active Aβ immunization in Alzheimer disease.
    Wisniewski T
    Nat Rev Neurol; 2019 Sep; 15(9):495-496. PubMed ID: 31308505
    [No Abstract]   [Full Text] [Related]  

  • 74. Active immunotherapy for Alzheimer's disease.
    Wisniewski T
    Lancet Neurol; 2012 Jul; 11(7):571-2. PubMed ID: 22677257
    [No Abstract]   [Full Text] [Related]  

  • 75. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.
    Petrushina I; Hovakimyan A; Harahap-Carrillo IS; Davtyan H; Antonyan T; Chailyan G; Kazarian K; Antonenko M; Jullienne A; Hamer MM; Obenaus A; King O; Zagorski K; Blurton-Jones M; Cribbs DH; Lander H; Ghochikyan A; Agadjanyan MG
    Neurobiol Dis; 2020 Jun; 139():104823. PubMed ID: 32119976
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
    Petrushina I; Davtyan H; Hovakimyan A; Davtyan A; Passos GF; Cribbs DH; Ghochikyan A; Agadjanyan MG
    Mol Ther; 2017 Jan; 25(1):153-164. PubMed ID: 28129111
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.
    Agadjanyan MG; Petrovsky N; Ghochikyan A
    Alzheimers Dement; 2015 Oct; 11(10):1246-59. PubMed ID: 26192465
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.
    Davtyan H; Ghochikyan A; Hovakimyan A; Davtyan A; Cadagan R; Marleau AM; Albrecht RA; García-Sastre A; Agadjanyan MG
    J Neuroimmunol; 2014 Dec; 277(1-2):77-84. PubMed ID: 25455094
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses.
    Davtyan H; Ghochikyan A; Movsesyan N; Ellefsen B; Petrushina I; Cribbs DH; Hannaman D; Evans CF; Agadjanyan MG
    Neurodegener Dis; 2012; 10(1-4):261-4. PubMed ID: 22301697
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.
    Davtyan H; Ghochikyan A; Cadagan R; Zamarin D; Petrushina I; Movsesyan N; Martinez-Sobrido L; Albrecht RA; García-Sastre A; Agadjanyan MG
    J Transl Med; 2011 Aug; 9():127. PubMed ID: 21806809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.